Mai Capital Management Macrogenics Inc Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Macrogenics Inc stock. As of the latest transaction made, Mai Capital Management holds 140 shares of MGNX stock, worth $403. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140Holding current value
$403% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MGNX
# of Institutions
131Shares Held
56MCall Options Held
28.3KPut Options Held
197K-
Bellevue Group Ag Kuesnacht, V89.93MShares$28.6 Million0.64% of portfolio
-
Armistice Capital, LLC New York, NY6.28MShares$18.1 Million0.29% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$15.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.32MShares$12.4 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.49MShares$10 Million0.06% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $177M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...